- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01508416
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (METRO)
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study
Patients with Multiple Myeloma (MM) are at increased risk of venous thromboembolic event, especially in newly diagnosed patients and during induction treatment with thalidomide in combination with dexamethasone. This association was mainly heightened during the 3 first months of chemotherapy.
Several coagulation abnormalities have been described. Laboratory tests measuring the overall thrombophilic tendency might be useful to assess thrombosis risk.
The aim of this study is to compare thrombin generation by calibrated automated thrombogram during the 3 first cycles of chemotherapy in patients with newly diagnosed MM.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Clermont-ferrand, Frankrike, 63000
- CHU de Clermont Ferrand
-
Nancy, Frankrike, 54000
- Chu de Nancy
-
Saint Etienne, Frankrike, 42055
- Service de Médecine Interne - CHU de Saint Etienne
-
Saint Etienne, Frankrike, 42055
- Service de rhumatologie - CHU de Saint Etienne
-
Saint Priest en Jarez, Frankrike, 42270
- Service d'hématologie - ICL
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Inscription to medical assurance
- Patients who gave their written consent
- Patients with newly diagnosed Multiple Myeloma required chemotherapy
Exclusion Criteria:
- Patients with renal failure who need to undergo hemodialysis
- Patients with indication for curative anticoagulant therapy
- Patient with 3 month follow-up not possible
- Patient with life expectancy < 6 month
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Patients with Multiple Myeloma
Patients with newly diagnosed Multiple Myeloma required chemotherapy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
change from baseline in Thrombin generation measure
Tidsramme: day 21
|
change from baseline in Thrombin generation measure
|
day 21
|
change from baseline in Thrombin generation measure
Tidsramme: day 42
|
change from baseline in Thrombin generation measure
|
day 42
|
change from baseline in Thrombin generation measure
Tidsramme: day 63
|
change from baseline in Thrombin generation measure
|
day 63
|
change from baseline in Thrombin generation measure
Tidsramme: day 0
|
change from baseline in Thrombin generation measure
|
day 0
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
image-confirmed venous thromboembolic events
Tidsramme: day 63
|
Estimate the incidence of venous thromboembolic events until day 63
|
day 63
|
change from baseline in TFPI resistance measure
Tidsramme: day 21
|
change from baseline in TFPI resistance measure
|
day 21
|
change from baseline in acquired protein S deficiency measure
Tidsramme: day 21
|
change from baseline in acquired protein S deficiency measure
|
day 21
|
change from baseline in TFPI resistance measure
Tidsramme: day 42
|
change from baseline in TFPI resistance measure
|
day 42
|
change from baseline in TFPI resistance measure
Tidsramme: day 63
|
change from baseline in TFPI resistance measure
|
day 63
|
change from baseline in acquired protein S deficiency measure
Tidsramme: day 42
|
change from baseline in acquired protein S deficiency measure
|
day 42
|
change from baseline in acquired protein S deficiency measure
Tidsramme: day 63
|
change from baseline in acquired protein S deficiency measure
|
day 63
|
change from baseline in TFPI resistance measure
Tidsramme: day 0
|
change from baseline in TFPI resistance measure
|
day 0
|
change from baseline in acquired protein S deficiency measure
Tidsramme: day 0
|
change from baseline in acquired protein S deficiency measure
|
day 0
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Bernard TARDY, MD-PhD, CHU de Saint-Etienne - CIC-EC (CIE3)
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Hematologiske sykdommer
- Hemoragiske lidelser
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Multippelt myelom
- Neoplasmer, plasmacelle
Andre studie-ID-numre
- 1108178
- 2011- A01529-32 (Annen identifikator: Afssaps)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Multippelt myelom
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)FullførtMyelom-multippel | Myelom, plasmacelleForente stater
-
National Cancer Institute (NCI)AvsluttetMyelom, multippel | Myelom-multippelForente stater
-
Tel-Aviv Sourasky Medical CenterFullførtPlasmacellemyelom | Myelom-multippel | Myelom multippel | Myelom, plasmacelleIsrael
-
National Cancer Institute (NCI)Georgetown University; Hackensack Meridian HealthAvsluttetMyelom-multippel | Myelom, plasmacelle | MyelomatoseForente stater
-
University of ChicagoNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...FullførtStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
University of Southern CaliforniaNational Cancer Institute (NCI); Celgene CorporationAvsluttetStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelomForente stater
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TilbaketrukketStage I Myelom | Stadium II multippelt myelom | Stadium III multippelt myelom